Reboxetine, fluoxetine and social functioning as an outcome measure in antidepressant trials: Implications

Primary Care Psychiatry

Volumn 4, Issue 2, 1998, Pages 81-89

  Healy, David ^a  

^a Hergest Unit   (United Kingdom)

Author keywords

Noradrenaline re uptake inhibition; Quality of life; Social functioning

Indexed keywords

FLUOXETINE; REBOXETINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL ADAPTATION; SOCIAL INTERACTION; TREATMENT OUTCOME;

EID: 0031822955     PISSN: 13552570     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Pychiatr 1960; 23:56-62.
2. Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 1997; 7 (Suppl. 1):57-70.
3. American Psychiatric Association. Diagnostic and Statistical Manual. Washington DC; 1987.
4. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour. European Neuropsychopharmacology 1997; 7 (Suppl 1):49-56.
5. Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health Education and Welfare; 1976. pp. 217-222.
6. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatr 1979; 134:382-389.
7. Healy D, McMonagle T. Enhancement of social functioning as a therapeutic principle in the management of depressive disorders. J. Psychopharmacol 1997; 11 (Suppl. 1):22-29.
8. Healy D. Metanalysis of trials comparing antidepressants with active placebos. Br J Psychiatr 1998; 172:232-234.
9. Stassen H, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs. Eur Psychiatr 1997; 12:166-176.
10. Healy D. The marketing of 5-hydroxytryptamine: depression or anxiety? Br J Psychiatr 1991; 158:737-742.
11. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin re-uptake inhibitors. Arch Gen Psychiatr 1994; 51:248-251.
12. Blier V, Bergeron R, de Montigny C. Selective activation of postsynaptic 5HT 1A receptors induces a rapid antidepressant response. Neuropsychopharmacol 1997; 16:333-338.
13. Anderson I. Meta-analysis of outcomes of clinical trials comparing SSRIs with TCAs. British Association for Psychopharmacology Annual Meeting, Cambridge, July 1997.
14. Lopez-Ibor JJ, Guelfi J, Pletan Y, Tournox A, Prost JF. Milnacipram and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996; 11 (Suppl. 4):41-46.
15. Wheatley D, Van Mofaert M, Timmerman L and the Mirtazapine Study Group. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with major depression. J Clin Psychiatr in press.
16. Hess W. Diencephalic, autonomic and extrapyramidal functions. Monogr Biol Med 1954.
17. Koella W. A modern neurobiological concept of vigilance. Experientia 1984;
18. Kielholz P. Die Behandlun endogener Depressionem mit Psychopharmaka. Deutsch Med Wochenschrft 1968; 93:701-710.
19. Carlsson A. Rationale and design of a selective inhibitor of 5-HT re-uptake. Br J Clin Pract Symp Suppl 1982; 19: 19-21.
20. Carlsson A. The rise of neuropsychopharmacology: impact on basic and clinical neuroscience. In: Healy D (editor) The Psychopharmacologists. London: Chapman & Hall; 1996. pp 1-12.
21. Garattini S. Experimental and clinical activity of antidepressant drugs. In Psychotropic Drug Development. Social, Economic and Pharmacological Aspects. Healy D, Doogan D (editors). London: Chapman & Hall; 1996. pp 1-12.
22. Claridge G, Healy D. The psychopharmacology of individual differences. Hum Psychopharmacol 1994; 9:285-298.
23. Cloninger CR. A unified biosocial theory of personality and its role in the development of anxiety states. Psychiatr Devel 1986; 3:167-226.
24. Van Praag H. "Make-Believes" in Psychiatry or The Perils of Progress. New York: Brunner-Mazel; 1992.
25. Healy D. The Antidepressant Era. Boston: Harvard University Press; 1997.
26. Joyce PR, Mulder RT, Cloninger CR. Temperament predicts clomipramine and desipramine response in major depression. J Affective Disord 1994; 30:35-46.
27. Nelson JC, Mazure C, Quinlan DM, Jatlow P. Drug responsive symptoms in melancholia. Arch Gen Psychiatr 1984; 41:663-668.
28. Nelson JC, Mazure C. A rating scale specific for tricyclic response in melancholia: the TRIM. J Clin Psychopharmacol 1990; 10:252-260.
29. Parker G, Hadzi-Pavlovicz D. Melancholia. A Disorder of Movement. Cambridge: Cambridge University Press; 1996.
30. Weissman MM, Klerman GL, Paykel ES, Prusoff BA, Hanson B. Treatment effects on the social adjustment of depressed patients. Arch Gen Psychiatr 1974; 30:771-778.
31. Elkington JR. Medicine and the quality of life. Ann Intern Med 1966; 64:711-714.
32. Katschnig H. How useful is the concept of quality of life in psychiatry? Curr Opin Psychiatr 1997; 10:337-345.
33. Turner R. Quality of life: experience with sertraline. Int Clin Psychopharmacol 1994; 9 (Suppl. 3):27-31.
34. Tuynman-Qua H, Jonghe F de, McKenna S, Hunt S. Quality of Life in Depression Rating Scale. Ibero, Houten, USA; 1992.
35. Stoker MJ, Dunbar GC, Beaumont G. The SmithKline Beecham "quality-of-life" scale: a validation and reliability study in patients with affective disorder. Qual Life Res 1992; 1:385-395.
36. Bech P. Quality of life instruments in depression. Eur Psychiatr 1997; 12:194-198.
37. Diener E. Subjective well being. Psychol Bull 1984; 95:542-575.
38. Bech P. Clinical effects of selective serotonin reuptake inhibitors. In Clinical Pharmacology in Psychiatry. Dahl SG, Gram LF (editors). Berlin: Springer Verlag; 1989. pp 82-93.
39. Healy D. The fluoxetine and suicide controversy. CNS Drugs 1994; 1: 223-231.
40. Fitzgerald K, Healy D. Dystonias and dyskinesias of the jaw associated with the use of SSRIs. Hum Psychopharmacol 1995; 10:215-219.
41. Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson RC, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatr 1998; 155:373-379.